Monthly Archives: October 2013

Six months ago the biotech industry was on the verge of a sizzling season for IPOs, and since then, on average, we’ve seen one new biotech IPO per week.  Valuations of many of these offerings have been impressive, and this

For the past 2.5 years I’ve been experimenting with this blog, covering topics about biotech startups, the pharma industry, and venture capital – so I thought it would be a good time for reflection. In my first blog post in

Last month legendary investor Vinod Khosla commented that 95% of VCs add “zero value” and 80% probably “add negative value” in how they advise startup companies in their portfolio.  This is a stunning indictment of the VCs that Khosla has

As you might expect given the strong IPO market, biotech venture investors are doing less of the heavy lifting in support of their portfolio companies during this receptive climate than in the past few years. Biotech insider participation was the